Dermatology Times (@DermTimesNow) header
Dermatology Times (@DermTimesNow) profile picture

A leading news resource serving dermatology clinicians.

North Olmsted, Ohio
Joined July 2009
Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)
Nail detachment: 39% of GLP-1 receptor agonist users vs 9% of matched controls. More from EADV 2026 ↓ hubs.li/Q04FCp690
292
🎀 DERMNEXUS 2026 IS UNDERWAY! Lauren Miller, conference chair, officially welcomes attendees to DermNexus 2026 in Scottsdale, Arizona, kicking off the first session of the meeting! #DermNexus2026 #DermatologyTimes #Dermatology #AdvancedPracticeProviders
217
EADV 2026 in review: the research and therapeutic advances that defined the congress ↓ hubs.li/Q04FCnbP0
1
269
Lisa Swanson, MD, returns to Don’t Be Rash to discuss newer nonsteroidal topical treatments and how they may fit into care for pediatric patients in this episode, supported by Arcutis. Β  Watch here: hubs.li/Q04FBk3x0 Β  #PediatricPsoriasis #DontBeRash
185
Zasocitinib tops deucravacitinib. 3 years of nemolizumab. New targets in lupus and HS. EADV 2026, at a glance ↓ hubs.li/Q04FClwb0
1
411
πŸ’‘ EXPERT INSIGHTS: How should clinicians interpret cross-trial efficacy data when selecting treatments for alopecia areata? πŸ”— Read more: Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment #AlopeciaAreata #JAKInhibitors #HairLoss #Dermatology
2
391
Can AI speed up skin cancer pathways? How many viral "glass skin" TikToks get it wrong? Swipe through EADV 2026 highlights ↓ hubs.li/Q04FBZn40
1
339
πŸ’‘ EXPERT INSIGHTS: Mark G. Lebwohl, MD, discusses anticipated monitoring requirements, the differences between oral and injectable therapies, and how disease severity and patient preferences can guide individualized treatment decisions. πŸŽ₯ Watch now: hubs.li/Q04FpLnW0
4
527
πŸ“‰ CLINICAL TRIAL UPDATE: Aclaris Therapeutics' investigational antibody bosakitug failed to meet the primary and secondary efficacy end points in a phase 2 trial for moderate to severe atopic dermatitis. hubs.li/Q04FpG-b0 #Bosakitug #AclarisTherapeutics
2
519